GlassScriptPhysician profile
Elizabeth Nelson
NPI 1942843388
$1,425.33
in general payments reported to CMS, 2019-2025
18 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.79 · 2022: $110 · 2023: $384 · 2024: $280 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $359.40 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Merz North America, INC. | $175.00 | 2023 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $127.93 | 2021-2025 | |
| Novo Nordisk INC | $125.99 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $107.44 | 2023-2025 | |
| Corcept Therapeutics | $103.21 | 2025 | Korlym |
| Lilly USA, LLC | $65.78 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $59.98 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $59.19 | 2022-2024 | |
| Boston Scientific Corporation | $49.09 | 2025 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $34.76 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $33.12 | 2022 | |
| Phathom Pharmaceuticals, INC. | $31.24 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $20.75 | 2023 | |
| Astellas Pharma US INC | $20.33 | 2024 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $20.22 | 2025 | Gomekli |
| Seqirus USA INC | $17.46 | 2025 | Flucelvax, Fluad |
| Dexcom, INC. | $14.44 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.